99 related articles for article (PubMed ID: 8125833)
1. A statistical evaluation of the bactericidal effects of ceftibuten in combination with aminoglycosides and ciprofloxacin.
Guérillot F; Carret G; Flandrois JP
J Antimicrob Chemother; 1993 Nov; 32(5):685-94. PubMed ID: 8125833
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
3. Pomegranate pericarp extract enhances the antibacterial activity of ciprofloxacin against extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL) producing Gram-negative bacilli.
Dey D; Debnath S; Hazra S; Ghosh S; Ray R; Hazra B
Food Chem Toxicol; 2012 Dec; 50(12):4302-9. PubMed ID: 22982804
[TBL] [Abstract][Full Text] [Related]
4. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
[TBL] [Abstract][Full Text] [Related]
5. [Comparative antibacterial activity of ceftibuten (SH 39 720) against 150 K. pneumoniae strains producing different beta-lactamases].
Thabaut A; Meyran M
Pathol Biol (Paris); 1990 May; 38(5):347-51. PubMed ID: 2195446
[TBL] [Abstract][Full Text] [Related]
6. In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta-lactamase.
Elkhaïli H; Kamili N; Linger L; Levêque D; Pompei D; Monteil H; Jehl F
Chemotherapy; 1997; 43(4):245-53. PubMed ID: 9209781
[TBL] [Abstract][Full Text] [Related]
7. Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics.
Sekowska A; Janicka G; Kłyszejko C; Wojda M; Wróblewski M; Szymankiewicz M
Med Sci Monit; 2002 Mar; 8(3):BR100-4. PubMed ID: 11889457
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Bedenic B; Vranes J; Suto S; Zagar Z
Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
[TBL] [Abstract][Full Text] [Related]
9. [Bactericidal effect of cefotaxime-sulbactam and imipenem combined with gentamicin and/or ciprofloxacin against CTX-1 producing Klebsiella pneumoniae].
Archambaud M; Labau E; Clave D; Suc C
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):534-9. PubMed ID: 2677925
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of minocycline combined with aminoglycosides against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
Wentao N; Guobao L; Jin Z; Junchang C; Rui W; Zhancheng G; Youning L
J Antibiot (Tokyo); 2018 May; 71(5):506-513. PubMed ID: 29416121
[TBL] [Abstract][Full Text] [Related]
11. Microbiologic profile of ceftibuten, a new oral cephalosporin.
Debbia EA; Pesce A; Chiesa M; Ricotta N; Schito GC
Drugs Exp Clin Res; 1992; 18(4):129-39. PubMed ID: 1451643
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan.
Liao CH; Sheng WH; Wang JT; Sun HY; Wang HK; Hsueh PR; Chen YC; Chang SC
J Microbiol Immunol Infect; 2006 Feb; 39(1):59-66. PubMed ID: 16440125
[TBL] [Abstract][Full Text] [Related]
13. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
Cherubin CE; Eng RH; Smith SM; Tan EN
J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from Western Norway.
Lindemann PC; Risberg K; Wiker HG; Mylvaganam H
APMIS; 2012 Jun; 120(6):495-502. PubMed ID: 22583362
[TBL] [Abstract][Full Text] [Related]
15. [Study of in vitro activity of 3 cephalosporins and their combination with 2 beta-lactamase inhibitors against 4 enterobacteria strains producing extended spectrum beta-lactamase].
Cattoen C; Duflos D; Bouillet L; Chatelain C; Mazars E
Pathol Biol (Paris); 1997 May; 45(5):425-9. PubMed ID: 9296097
[TBL] [Abstract][Full Text] [Related]
16. [The rate of isolation of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and resistance to antibiotics].
Vitkauskiene A; Dudzevicius V; Ryskus L; Adukauskiene D; Sakalauskas R
Medicina (Kaunas); 2006; 42(4):288-93. PubMed ID: 16687900
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides.
Joly-Guillou ML; Decré D; Herrman JL; Bourdelier E; Bergogne-Bérézin E
J Antimicrob Chemother; 1995 Oct; 36(4):619-29. PubMed ID: 8591936
[TBL] [Abstract][Full Text] [Related]
18. Transferable resistance to cefotaxime in nosocomial Klebsiella pneumoniae and Escherichia coli strains due to their production of extended-spectrum beta-lactamase in Slovakia.
Hupková M; Blahová J; Babálová M; Krcméry V; Králiková K
J Chemother; 1995 Feb; 7(1):16-20. PubMed ID: 7629551
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergy of cefamandole-tobramycin combinations.
Valenti AJ; Siniscalchi AJ; Andriole VT
Yale J Biol Med; 1977; 50(2):177-82. PubMed ID: 331694
[TBL] [Abstract][Full Text] [Related]
20. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
